-
1 month ago | 
dermatologytimes.com | Kaitlyn Bader |Christopher G. Bunick
“When it comes to oral antibiotics, one of the topics I focused on is the fact that antibiotic stewardship is needed. I also like to say that we are honorary gastroenterologists in dermatology because the antibiotics we prescribe affect the gut. We know that the gut microbiome is so important to human health,” said Christopher Bunick, MD, PhD, in an interview at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida.
-
1 month ago | 
dermatologytimes.com | Kaitlyn Bader |Christopher G. Bunick
“We have benzoyl peroxide products that are forming benzene, some of them at levels above the conditional limit and are not lasting to the point of the expiration date on the product. This is a regulatory problem. These products are not in line with the FDA regulatory standard, and this is an opportunity for innovation in dermatology,” said Christopher Bunick, MD, PhD, in an interview at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida.
-
1 month ago | 
dermatologytimes.com | Kaitlyn Bader |Christopher G. Bunick
L’Oréal announced today it is recalling all lots of its acne treatment Effaclar Duo in the US due to concerns over benzene contamination.1 The product, sold under the La Roche-Posay brand, contains benzoyl peroxide (BPO).
-
1 month ago | 
healio.com | Gabrielle Capaldo |Kristen Dowd |Christopher G. Bunick
Key takeaways: Formulations suggestive of higher temperature processing were associated with greater benzene concentrations. This included those with higher melting point emulsifiers or surfactants. Formulation may be the primary factor responsible for the presence of high benzene levels in benzoyl peroxide-containing acne products stored at room temperature, according to published results.
-
2 months ago | 
healio.com | Christopher G. Bunick |Kristen Dowd
MIAMI BEACH, Fla. — Janus kinase inhibitors are an incredibly important, new tool that have exemplified both high efficacy and safety, according to a speaker at South Beach Symposium. In an interview with Healio, Christopher G. Bunick, MD, PhD, associate professor of dermatology at Yale School of Medicine and South Beach Symposium senior planning committee member, discussed the session he chaired on Janus kinase (JAK) inhibitors at this year’s symposium.
-
Jan 6, 2025 | 
dermatologytimes.com | Christopher G. Bunick
Dermatology Times recently sat down with its newest Editor in Chief, Christopher Bunick, MD, PhD, to learn more about his research, career goals, mentorship advice, and more. Q: How does your work in x-ray crystallography and cryogenic electron microscopy (cryo-EM) contribute to research advancements in dermatology?
-
Nov 22, 2024 | 
dermatologytimes.com | Kaitlyn Bader |Christopher G. Bunick
“My personal experience has been, however, that the patients who suffer the most in terms of their quality of life detriment are those that experience those deep, painful fissures on the hands, particularly on the fingers, and that's usually accompanied by swelling,” said Christopher Bunick, MD, PhD, in an interview with Dermatology Times on recent chronic hand eczema (CHE) and delgocitinib cream updates.
-
Nov 1, 2024 | 
dermatologytimes.com | Kaitlyn Bader |Christopher G. Bunick
“When we apply the molecular dynamics analysis to rademikibart, and IL-4 receptor alpha [IL-4Rα], we see strong stability of this antibody antigen complex, suggesting that rademikibart truly is a next-generation optimized IL-4Rα inhibitor, and this explains why it has twice the binding affinity to IL-4Rα as dupilumab,” said Christopher Bunick, MD, PhD, in an interview with Dermatology Times at Fall Clinical 2024 in Las Vegas, Nevada.
-
Nov 1, 2024 | 
dermatologytimes.com | Kaitlyn Bader |Christopher G. Bunick
“When we apply the molecular dynamics analysis to rademikibart, and IL-4 receptor alpha [IL-4Rα], we see strong stability of this antibody antigen complex, suggesting that rademikibart truly is a next-generation optimized IL-4Rα inhibitor, and this explains why it has twice the binding affinity to IL-4Rα as dupilumab,” said Christopher Bunick, MD, PhD, in an interview with Dermatology Times at Fall Clinical 2024 in Las Vegas, Nevada.
-
Oct 30, 2024 | 
dermatologytimes.com | Kaitlyn Bader |Christopher G. Bunick
“This data is very encouraging to clinicians. When you put a patient on a JAK inhibitor, you can tell them that the oral JAK inhibitors have this ability to maintain response for a long period of time. You're not necessarily going to have to be changing medicines all the time. This one medicine, upadacitinib, can get the job done for a long period of time,” said Christopher Bunick, MD, PhD, in an interview with Dermatology Times at Fall Clinical 2024 in Las Vegas, Nevada.
